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Background: Multicomponent non-pharmacological therapies have been shown to 
be effective at reducing cognitive symptoms and slowing deterioration in abilities 
to perform activities of daily living (ADL) in individuals with cognitive impairment. 
However, little is known about response rates and predictors of response.
Methods: We used data from the German day-care study (DeTaMAKS; De  = 
dementia, Ta = Tagespflege/day-care, M = motor stimulation, A = activities of daily 
living stimulation, K = k/cognitive stimulation, S = social stimulation; n = 362), which 
was based on a cluster-randomized trial of the non-pharmacological, multicomponent, 
anti-dementia MAKS therapy for people with cognitive impairment in day-care 
centers. We investigated response (defined as improvement or no deterioration) for 
three different response criteria: cognition via Mini-Mental State Examination (MMSE) 
score, ADL via Erlangen Test of Activities of Daily Living in Persons with Mild Dementia 
or Mild Cognitive Impairment (ETAM) score, and behavioral and psychological 
symptoms of dementia (BPSD) via Neuropsychiatric Inventory Questionnaire (NPI-Q) 
score. In addition, we calculated the number needed to treat (NTT) and response 
rates according to net gain analyses.
Results: For all three criteria, the response rates were higher in the intervention 
group than in the control group (chi2 test: p = 0.058 to p = 0.003). Compared 
with non-responders, responders according to cognition had higher ETAM scores 
(= better ADL abilities) at baseline; responders according to ADL had lower ETAM 
scores (= poorer ADL abilities) at baseline; and responders according to BPSD had 
higher NPI-Q scores (= more BPSD) at baseline. Classification rates based on these 
predictors ranged from 60.6 to 68.3%.
Discussion: The response rates to the non-pharmacological MAKS therapy were 
greater than those reported for anti-dementia drugs. There were only a few differences 
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INTRODUCTION
According to the World Health Organization (WHO) (1), the total 
number of individuals with dementia worldwide is estimated at 
50 million and may triple within the next 30 years. Dementia is 
already the second leading cause of need for care among older 
people, and it has a large impact on the psychological well-being 
of caregivers and families (2). There have also been dramatic 
increases in the costs of medical care and the societal burdens 
associated with this disease (3).
In cholinesterase inhibitor (CEI) trials, intervention groups 
(IGs) have shown around 14 to 37% more responders on cognitive 
outcomes than placebo groups, depending on the drug, severity 
of dementia, and response criterion (4). Yet, a recent cohort 
analysis called into question the long-term effects by showing 
that initial improvement on the Mini-Mental State Examination 
(MMSE) seemed to vanish after about 1 year of treatment (5). 
In addition, treatment with CEIs was associated with adverse 
effects such as bradycardia or syncope (6). In a recent responder 
analysis for patients with mild to moderate Alzheimer’s disease 
treated with Donepezil, differences in the response rates of the IG 
versus the placebo group of 12 to 16% were found on cognitive 
outcomes (7).
Medical guidelines on the treatment of dementia from the 
NICE Institute (8) as well as its German equivalent (9) recommend 
the use of non-pharmacological therapies such as cognitive 
stimulation or the occupational training of activities of daily 
living (ADL); both of which are on a par with pharmacological 
treatment via CEIs. Non-pharmacological therapies addressing 
cognition, ADL, and BPSD have been shown to be effective in 
a variety of trials. For example, cognitive stimulation showed 
beneficial effects on cognition in addition to medication (10). 
Physical activity led to a reduction in BPSD (11) and showed 
promising results for the improvement of ADL (12). However, 
in a recent review, the quality of these studies was regarded 
as mostly low (13). In recent research, non-pharmacological 
multicomponent therapies seemed to be more effective than 
one-component therapies because they had positive effects on 
more than one outcome domain (14, 15). In two high-quality-
randomized controlled trials, MAKS therapy, a multicomponent 
group therapy for people with mild cognitive impairment and 
mild to moderate dementia (components: motor stimulation, M; 
activities of daily living stimulation, A: k/cognitive stimulation, 
K; social stimulation, S), was shown to be effective in maintaining 
the cognitive and ADL abilities of elderly individuals with 
cognitive impairments, living either in nursing homes (16, 17) 
or in the community (18). Yet, to our knowledge, responder 
analyses for non-pharmacological therapies targeting cognitive 
impairment (mild cognitive impairment and mild to moderate 
dementia) have not been published, whereas several studies have 
explored responses to pharmacological therapies (19).
A response is usually defined as a stabilization or improvement 
in dementia symptoms. According to ICD 10 criteria (20), no 
response is defined as the further progression of dementia-
associated symptoms: a) cognitive decline, b) a deterioration 
in activities of daily living, and c) an increase in behavioral 
psychological symptoms of dementia (BPSD).
Several variables might influence or even predict response: 
whether or not a person responds to an intervention might 
depend on several factors regarding the person with dementia 
(PWD) himself/herself and factors regarding the environment 
of the PWD (e.g., a caregiving relative). Possible predictors 
of response referring directly to the PWD might be diseases 
involving physical impairment of the upper extremities 
(which might particularly influence component M “motor 
stimulation”) (21), sex (which might particularly influence 
component A “activities of daily living stimulation,” especially 
in this generation) (22), severity of cognitive impairment 
(which might particularly influence component K “k/cognitive 
stimulation,” as cognitive stimulation is recommended for the 
earlier stages of dementia) (9), agreeableness (which might 
particularly influence component S “social stimulation”) 
(23), depressive symptoms [which might influence all four 
components M, A, K, and S, see e.g., Watts et al. (24)], and 
age. Possible predictors of response referring to the PWD’s 
environment might be a stimulating environment outside of 
day care, living alone/living with the caregiving relative, abusive 
behavior at home, and the burden and age of the caregiver.
The aim of this paper is to perform a responder analysis of 
MAKS therapy with the outcome criteria cognition, ADL, and 
BPSD and to identify the predictors of response. This analysis 
should allow us to identify treatment responders as well as the 
between responders and non-responders. Because of the low classification rates, 
these variables had only a small impact on response predictions. Therefore, there are 
no empirically substantiated selection criteria for the application of MAKS therapy in 
facilities.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier ISRCTN16412551.
Keywords: dementia, cognitive impairment, multicomponent intervention, non-pharmacological intervention, 
responder analysis
Abbreviations: ADL, Activities of daily living; BIZA-D, Berliner Inventar zur 
Angehörigenbelastung – Demenz; BPSD, Behavioral and Psychological Symptoms 
of Dementia; BSFC-s, Burden Scale for Family Caregivers—short version; CEI, 
Cholinesterase inhibitor; CG, Control group; ETAM, Erlangen Test of Activities 
of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment; 
IG, Intervention group; MMSE, Mini-Mental State Examination; NPI-Q, 
Neuropsychiatric Inventory Questionnaire; NTT, Number needed to treat; PRO, 
Patient-reported outcome; PWD, Person with dementia. 
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most promising treatments. It may also help to improve their 
cost-effectiveness.
Research questions:
1) How many responders are in the intervention group (IG) 
versus the control group (CG) for the different response 
criteria?
2) Do any of the variables predict response—analyzed separately 
for the different response criteria?
MATERIALS AND METHODS
Design
The present analyses were computed on the per protocol sample 
from the German day-care study and included 362 day-care 
users. The German day-care study (DeTaMAKS) is a cluster-
randomized controlled trial, which was conducted in 32 day-care 
centers throughout Germany (25). The day-care centers were 
randomly assigned to either the IG or the CG, stratified by region. 
In the IG (16 day-care centers), MAKS therapy, a multimodal non-
pharmacological training for people with cognitive impairment, 
was offered once a day. Participants received MAKS therapy each 
day they visited the day-care center (between 1 and 5 days per 
week). In the CG (16 day-care centers), participants received 
“care as usual,” which included offers of stimulating treatments 
besides MAKS to all participants in the day-care center (active 
control group) and treatment with anti-dementia drugs (about 
30% of the whole sample). The study design is described in detail 
in Behrndt et al. (25).
Intervention
MAKS therapy is a structured, multimodal, non-pharmacological 
therapy that addresses the following components: (psycho) 
motor capabilities (M), ADL abilities (A), cognitive functioning 
(K), and social components (S). The therapy is manualized, and 
a unique program is offered every day, each addressing all four 
components. These include, for example, discussions of personal 
topics with seasonal references (social), table football (motor), 
crafting a bird box (ADL), and playing a specially adapted 
version of “Who Wants to be a Millionaire” projected on a screen 
(cognition). Qualified staff members working in the day-care 
centers were trained for 2 days to use and apply the materials 
in the manual. They subsequently offered a 2-h MAKS therapy 
session every day. For a detailed description of the intervention 
and its implementation, see Behrndt et al. (25) and Straubmeier 
et al. (18).
Implementation fidelity was ensured by 1) a structured 2-day 
training for the persons conducting MAKS in the day-care center, 
2) the MAKS instruction manual with detailed instructions how 
to perform the intervention, 3) documentation by the MAKS 
therapists in the day-care centers to monitor the intensity and 
quality of the MAKS therapy in the intervention group, and 
4) monitoring by the study headquarters staff in the day-care 
centers during the first 6 months in a random sample of four 
day-care centers (investigating treatment adherence/conduct of 
MAKS therapy, quality of the documentation, and attendance of 
the study participants).
Data Collection
Data were collected from all participants at baseline and after 
the intervention had run for 6 months. Data were obtained 
from the day-care users in three different ways. First, the Mini-
Mental State Examination (MMSE, cognitive performance) and 
the Erlangen Test of Activities of Daily Living in Persons with 
Mild Dementia or Mild Cognitive Impairment (ETAM, ADL 
performance) were assessed directly by trained staff members 
who worked at the day-care centers but were not involved in 
the MAKS therapy. Second, proxy ratings of BPSD were given 
by the primary caregiver via telephone interviews conducted by 
trained researchers from the study headquarters. Third, data on 
medications were obtained directly from the documentation of 
the day-care centers.
Instruments
Predictor Variables (Assessed at Baseline): PWD 
Data
Charlson Comorbidity Index (26, 27): The Charlson 
Comorbidity Index (26) was updated by Quan et al. 
(27) and is used to calculate the effect of any previous 
medical diagnoses on the mortality rate. Thus, it assigns 
weights to comorbidities according to their severity. 
The 1-year mortality increases from 12% (index = 0) to 
85% (index ≥ 5) as the score increases (26).
Care level: The care level describes the extent of 
independence in daily life and ranges from none (fully 
independent) to level 5 (most severe impairment to 
independence with special demands placed on nursing 
care). In Germany, this scale is used as a reference point 
to classify a person’s entitlement to care services from 
the German long-term care insurance (German system 
of statutory long-term care funds).
Anti-dementia drugs: Anti-dementia drugs (memantine 
and cholinesterase inhibitors) were assessed with the 
documentation system used by the day-care centers.
Depressive symptoms: Depressive symptoms were 
assessed with the depression item from the 
Neuropsychiatric Inventory Questionnaire (NPI-Q) 
(28). For more information, see the description of the 
NPI-Q in the outcome section.
CNS depressant score: The central nervous system 
(CNS) depressant score was formed in the following 
way: all medications were independently rated by two 
experts—both professors of clinical pharmacology 
at the University of Erlangen-Nürnberg—on a scale 
comprised of “very CNS depressant” (−2), “CNS 
depressant” (−1), “neutral” (0), “CNS activating” (+1), 
and “very CNS activating” (+2). The scores from a 
PWD’s medications were summed and formed the 
PWD’s CNS depressant score.
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Orthopedic and neurological diseases: Orthopedic 
diseases (e.g., arthrosis, polyarthritis, gout; included 
ICD codes [not all present in the sample]: M06, M10, 
M15, M16, M17, M19, M20, M25, M41, M42, M43, 
M47, M48, M51, M54, M62, M79, M80, M81, M93) 
and neurological diseases (e.g., Parkinson’s disease, 
multiple sclerosis, stroke; included ICD codes [not 
all present in the sample]: G20, G21, G25, G35, G36, 
G40, G41, G43, G45, G50, G62, G63, G70, G71, G72, 
G81, G83, G90, G91, G93, I63, I64) were assessed 
with the documentation system used by the day-care 
centers.
Predictor Variables (Assessed at Baseline): 
Caregiver Variables
Burden scale for family caregivers—short version (BSFC-s) 
(29): The BSFC-s is used to assess the subjective burden 
of informal caregivers. The 10 items are rated on a scale 
ranging from 0 (strongly disagree) to 3 (strongly agree). 
The total score ranges from 0 to 30 points, with higher 
values indicating greater burden.
Positive aspects of caregiving: the Berlin Inventory of 
Caregivers’ Burden with Dementia Patients (Berliner 
Inventar zur Angehörigenbelastung—Demenz, BIZA-D) 
(30) contains a 5-item subscale for “benefits” rated on a 
five-point Likert scale (0–4). The sum score ranges from 
0 to 20 points, with higher values indicating that the 
caregiver is experiencing the more positive aspects of 
caregiving.
The age of the caregiving relative, the degree of kinship to the 
PWD, and whether the caregiver lived in the same house with 
the PWD (shared or separate households) were also assessed via 
telephone interviews with the primary caregiver.
Outcome Variables (Assessed at Baseline and After 
6 Months in the Intervention): Dementia Symptoms
Mini-Mental State Examination (MMSE) (31): The 
MMSE measures five areas of cognitive functioning: 
orientation, registration, attention and calculation, recall, 
and language. The score ranges from 0 to 30 points, with 
higher scores representing better cognitive performance. 
This is the most often used screening test for dementia 
worldwide and thus provides good comparability with 
other studies. Furthermore, the MMSE is suitable for the 
assessment of cognitive function in longitudinal studies 
when basic information on cognition is sufficient (32).
Erlangen Test of Activities of Daily Living in Persons with 
Mild Dementia or Mild Cognitive Impairment (ETAM) 
(33): The ETAM is a short performance test for the 
assessment of the ability to perform ADL in people with 
mild dementia or mild cognitive impairment. The score 
ranges from 0 to 30 points, with higher values showing 
better abilities to perform ADL (33).
Neuropsychiatric Inventory Questionnaire (NPI-Q) (28): 
The NPI-Q is an observer rating scale for the evaluation 
of neuropsychiatric symptoms by the informal caregiver 
covering the 12 symptom areas: delusions, hallucinations, 
agitation/aggression, depression/dysphoria, anxiety, 
elation/euphoria, apathy/indifference, disinhibition, 
irritability/lability, motor disturbance, night-time 
behaviors, and appetite/eating. In the DeTaMAKS 
project, the NPI-Q symptoms were assessed only 
dichotomously (presence or absence of a symptom). The 
sum score therefore ranges from 0 to 12 points. Here, the 
NPI-Q score was used as a proxy for BPSD.
Definition of Response
Because a deterioration of three MMSE points per year can be 
expected in untreated dementia patients (34, 35), we formed three 
groups that reflected different levels of MMSE change: responders 
(improvement or no deterioration in 6 months), expected 
deteriorators (deterioration ≤1.5 MMSE points in 6 months), and 
pronounced deteriorators (deterioration >1.5 MMSE points in 
6 months).
Furthermore, three response criteria were formed on the basis of 
the ICD criteria for dementia: a) cognition (MMSE score), b) ADL 
(ETAM score), and c) BPSD (NPI-Q score as the number of BPSD 
items). For all three criteria, response was defined as improvement 
or no deterioration according to the National Institute for Health 
and Care Excellence (NICE) guideline (4).
Statistical Analyses
The means, standard deviations, minima, maxima, and 
frequencies (when appropriate) were given for all variables to 
provide an overview.
Group differences regarding non-normally distributed variables 
were calculated using Mann–Whitney U-tests. The variables 
that differed between responders and non-responders were used 
as predictors in binary logistic regression analyses. These were 
calculated to analyze the classification rates for the three response 
criteria. The baseline scores of the outcome variables are also used as 
potential predictor variables to control for baseline differences.
Group differences regarding the numbers of responders in 
the IG and in the CG were calculated using chi2 tests (according 
to Fisher). In addition, a net gain analysis (36) was computed 
for the three MMSE groups. The net gain was defined as  (% 
respondersIG—% respondersCG—[% deterioratorsIG—% 
deterioratorsCG]) (36). The number needed to treat (NNT; how 
many patients must undergo MAKS therapy for one more patient 
to remain stable/improve) was calculated for all response criteria.
RESULTS
Description of the Sample
Sixty one percent of the participants were women, and the mean 
age of the sample was 81.3 years (SD = 7.5). Participants achieved 
a mean MMSE value of 19.6 (SD = 4.8) with cognitive impairment 
ranging from mild cognitive impairment to mild and moderate 
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dementia. The rate of people with mild cognitive impairment 
[defined as MMSE ≥24 and Montreal Cognitive Assessment 
(MoCA) ≤22 (18)] did not differ between intervention and control 
group (chi², Fisher’s exact test, p = 0.444). Around one third of 
all participants were treated with anti-dementia drugs (CEIs or 
memantine). Detailed descriptive data of the IG, the CG, and the 
whole sample are presented in Table 1. There were no significant 
differences between the IG and CG on the baseline data except the 
CNS depressant score (CG-PWDs had a higher CNS depressant 
score than IG-PWDs) and the variable reflecting whether the 
caregiver lived in the same house with the PWD (CG-PWDs were 
more likely to live in the same house with their caregiver).
Comparison of the IG and CG on Expected 
MMSE Change
For the CG, the mean MMSE change was a deterioration (−0.9 
MMSE points), whereas for the IG, the mean MMSE change was 
a very slight improvement (+0.1 MMSE points). This difference 
was significant (Mann–Whitney U-test, p = 0.008). For the three 
MMSE change groups, the following results emerged: in the IG 
(versus the CG), the percentage of responders was significantly 
higher, the percentage of pronounced deteriorators was 
significantly lower, and the percentage of expected deteriorators 
was similar (see Table 2 for details). The net gain analysis showed 
an advantage of 28% for the IG.
Comparison of IG and CG Regarding the 
Response Criteria Cognition, ADL, and 
BPSD
For all three response criteria, the percentage of responders 
was higher in the IG compared with the CG. This difference 
was significant for cognition and ADL, but there was only a 
trend toward significance for BPSD (see Table 3). The NNT 
was 7 for the criteria cognition and ADL and 10 for BPSD.
TABLE 1 | Baseline characteristics of the sample.
Whole sample 
(N = 362) 
Intervention 
group (n = 208)
Control group 
(n = 154)
p for group 
differences 
between 
intervention and 
control group
PWD 
variables at 
baseline
Age (in years) M ± SD 81.3 ± 7.5 (46–99) 81.5 ± 7.5 (53–99) 81.1 ± 7.5 (46–93) 0.701a 
Sex (female) % (n) 61.0% (n = 221) 61.1% (n = 127) 61.0% (n = 94)  >0.999b 
Education (years of school 
attendance)
 <8 years
8–9 years
9–10 years
12–13 years
university
% (n) 6.4% (n = 23)
70.2% (n = 254)
12.7% (n = 46)
5.0% (n = 18)
5.8% (n = 21)
6.7% (n = 14)
69.7% (n = 145)
12.0% (n = 25)
4.8% (n = 10)
6.7% (n = 14)
5.8% (n = 9)
70.8% (n = 109)
13.6% (n = 21)
5.2% (n = 8)
4.5% (n = 7)
0.910b
Dementia 
symptoms
Cognition (MMSE) M ± SD 19.6 ± 4.8 (10–30) 19.8 ± 4.8 (10–30) 19.3 ± 4.8 (10–30) 0.267a 
ADL (ETAM) M ± SD 17.6 ± 7.2 (0–30) 17.9 ± 6.9 (0–30) 17.1 ± 7.5 (2–30) 0.340a 
BPSD (NPI-Q) M ± SD 5.3 ± 2.7 (0–11) 5.2 ± 2.7 (0–11) 5.4 ± 2.7 (0–11) 0.572a 
Medical 
variables
Charlson Comorbidity Index M ± SD 2.2 ± 1.6 (0–8) 2.3 ± 1.6 (0–8) 2.1 ± 1.6 (0–7) 0.425n.s.a 
Anti-dementia drugs1 (yes) % (n) 28.2% (n = 102) 29.8% (n = 62) 26% (n = 40) 0.479b 
Care level M ± SD 2.9 ± 0.8 (1–5) 2.9 ± 0.8 (1–5) 3.0 ± 0.9 (1–5) 0.362a 
Depression (NPI-Q) M ± SD 0.6 ± 0.5 (0–1) 0.6 ± 0.5 (0–1) 0.6 ± 0.5 (0–1) 0.721a
CNS depressant score M ± SD −1.1 ± 1.6 (−10–1) −1.0 ± 1.5 (−10–1) −1.4 ± 1.7 (−8–1) 0.019a
Orthopedic diseases % (n) 27.9% (n = 101) 28.8% (n = 60) 26.6% (n = 41) 0.722b
Neurological diseases % (n) 24.3% (n = 88) 21.6% (n = 45) 27.9 (n = 43)% 0.175b
Caregiver 
variables at 
baseline
Age (in years) M ± SD 59.5 ± 11.4 
(25–87)
59.6 ± 11.6 
(27–87)
59.3 ± 11.2 
(25–86)
0.801a 
Sex (female) % (n) 74.6% (n = 270) 73.1% (n = 152) 76.6% (n = 118) 0.466b
Education (years of school 
attendance)
 <8 years
8–9 years
9–10 years
12–13 years
University
% (n) 1.4% (n = 5)
39.2% (n = 142)
35.9% (n = 130)
12.2% (n = 44)
11.3% (n = 41)
2.4% (n = 5)
38.5% (n = 80)
33.7% (n = 70)
13.9% (n = 29)
11.5% (n = 24)
0.0% (n = 0)
40.3% (n = 62)
39.0% (n = 60)
9.7% (n = 15)
11.0% (n = 17) 
0.229b
Burden (BSFC-s) M ± SD 12.5 ± 8.0 (0–30) 12.0 ± 8.2 (0–29) 13.2 ± 7.6 (0–30) 0.097a
Benefits (BIZA-D) M ± SD 12.6 ± 5.1 (0–20) 12.5 ± 4.9 (0–20) 12.6 ± 5.4 (0–20) 0.756a
Degree of 
kinship to 
the PWD
Spouse % (n) 30.4% (n = 97) 30.0% (n = 54) 30.9% (n = 43) 0.756b
Parent % (n) 58.9% (n = 188) 59.4% (n = 107) 58.3% (n = 81)
Parent-in-law % (n) 6.6% (n = 21) 5.6% (n = 10) 7.9% (n = 11)
Other relative % (n) 3.5% (n = 11) 4.4% (n = 8) 2.2% (n = 3)
Neighbor/friend % (n) 0.6% (n = 2) 0.6% (n = 1) 0.7% (n = 1)
Living in the same house with the PWD (yes) % (n) 61.0% (n = 221) 56.2% (n = 117) 67.5% (n = 104) 0.038b
aMann-Whitney U-test; bChi², Fisher’s exact test; 1CEIs or memantine.
ADL, Activities of daily living; BIZA-D, The Berlin Inventory of caregivers’ burden with dementia patients (Berliner Inventar zur Angehörigenbelastung – Demenz); BSFC-s, Burden 
scale for family caregivers – short version; CNS, Central vervous system; ETAM, Erlangen test of activities of daily living in persons with mild dementia or mild cognitive impairment; 
MMSE, Mini-mental state examination; NPI-Q, Neuropsychiatric inventory questionnaire.
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Comparison of Responders and Non-
Responders in the IG for the Response 
Criteria Cognition, ADL, and BPSD
For each of the three response criteria, we found at least one 
significant difference between responders and non-responders 
(see Table 4):
• Responders according to the cognition criterion had higher 
ETAM scores at baseline than non-responders (19.2 versus 
16.0 points), and their caregivers` education was higher.
• Responders according to the ADL criterion had lower ETAM 
scores at baseline than non-responders (16.4 versus 20.2 points).
• Responders according to the BPSD criterion had higher NPI-Q 
scores at baseline than non-responders (5.5 versus 4.4 points).
The mean changes in the three criteria were improvements 
(MMSE score: M = 0.1, SD = 3.8, range: −13 to 15; ETAM score: 
M = 0.3, SD = 4.0, range: −11 to 12; NPI score: M = 0.1, SD = 1.8, 
range: −6 to 7).
The rate of people with mild cognitive impairment did not 
differ between responders and non-responders according to 
the cognition criterion (chi², Fisher’s exact test, p = 0.328), the 
ADL criterion (chi², Fisher’s exact test, p = 0.869), and the BPSD 
criterion (chi², Fisher’s exact test, p = 0.292).
Binary logistic regression analyses with the variables that 
differed significantly between responders and non-responders 
as predictors and response versus non-response as the outcome 
variable were significant for all three response criteria. The 
explained variance ranged from 5.5% (BPSD) to 10.1% (ADL) to 
10.6% (cognition). The rates of correct classification varied from 
63.9% (cognition) to 64.9% (ADL) to 68.3% (BPSD).
DISCUSSION
The treatment of dementia remains a great challenge. To optimize 
health care, it is important to develop effective treatment methods, 
to evaluate them properly, and to identify groups of PWDs that 
might profit the most. In this paper, we conducted a responder 
analysis for the previously evaluated non-pharmacological 
multicomponent MAKS therapy for individuals with cognitive 
impairments in day-care centers. We analyzed several factors 
regarding the PWD, the caregiver, and the care situation that we 
expected that might influence response.
Our main findings were as follows: 1) for the response criteria 
cognition and ADL, there were more responders in the IG 
compared with the CG. 2) For the cognition criterion, responders 
had higher baseline scores regarding activities of daily living than 
non-responders, but it was the opposite for the ADL criterion. 
3) For the BPSD criterion, responders had higher baseline scores 
regarding BPSD than non-responders. 4) Because of the low 
classification rates, these variables had only a small impact on the 
prediction of response.
Superiority of the IG Compared With 
the CG
As expected on the basis of earlier studies (16–18), we found 
that the MAKS intervention was superior to the active control 
group—all were offered stimulating interventions besides MAKS 
in their day-care centers (“care as usual”). The mean MMSE 
score declined for the CG and remained constant for the IG. A 
deterioration of three MMSE points per year can be expected 
in untreated dementia patients (34, 35) because dementia is a 
progressive disease. Thus, the deterioration of one MMSE point 
during the 6-month period in the CG was nearly as high as it 
would be expected. The superiority of the IG was not only due 
to significantly higher response rates but also to significantly 
lower rates of pronounced deteriorators compared with the CG. 
This underlines the special meaning of non-pharmacological 
interventions such as MAKS, which is designed not only to 
improve cognition but also to delay the deterioration that is to be 
expected from the progression of the disease.
Depending on the criterion, we found response rates ranging 
from 58 to 69% in the IG. The response rate of 58% for the 
cognition criterion in our study was slightly higher than the 
response rate of 53.7% (for stabilization or improvement on 
TABLE 2 | Numbers of responders, expected deteriorators, and pronounced deteriorators regarding MMSE.
Intervention group (n = 208) Control group (n = 154) Delta of the percentage
of responders
p (Chi2 test, Fisher’s 
exact test) 
Responders (improvement or 
no deterioration)
58% (n = 121) 42% (n = 65) 16% 0.003
Expected deteriorators 
(deterioration ≤1.5 MMSE 
points)
13% (n = 26) 17% (n = 26) 4% 0.289
Pronounced deteriorators 
(deterioration >1.5 MMSE 
points)
29% (n = 61) 41% (n = 63) 12% 0.025
MMSE, Mini-mental state examination; NPI-Q, Neuropsychiatric inventory questionnaire.
TABLE 3 | Response to the MAKS intervention.
Response 
criterion
Percentage of responders Delta of the 
percentage of 
responders
p (Chi2 test, 
Fisher’s 
exact test) Intervention 
group 
(n=208)
Control 
group 
(n=154)
Cognition 58% (n=121) 42% (n=65) 16% 0.003
ADL 61% (n=126) 45% (n=70) 16% 0.005
BPSD 69% (n=144) 59% (n=91) 10% 0.058
ADL, activities of daily living; BPSD, behavioral and psychological symptoms of 
dementia.
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the MMSE) after 6 months of cholinesterase-inhibitors (CEI) 
treatment reported by Droogmsa et al. (37).
Differences in the response rates between the IG and CG 
ranged from 12 to 16% (depending on the criterion), with 
NNT values ranging from 7 to 10, respectively. Although it is 
very difficult to compare response rates across different studies 
because of the great variety of response criteria, MAKS therapy 
seems to be at least as effective as CEIs. Burns et al. (7), for 
example, found similar differences in the response rate of 16% 
between the IG (donepezil) and CG for cognition measured with 
the MMSE. Yet, it must be noted, that both in the IG and the 
CG of our study, almost one third of each group received anti-
dementia drugs.
Differences Between Responders and 
Non-Responders in the IG as Predictors 
of Response
For all three response criteria (cognition, ADL, BPSD), we did not 
find differences between responders and non-responders in the IG 
regarding the MMSE and education at baseline. MAKS seems to 
be suitable for all included levels of cognitive impairment (mild 
cognitive impairment, mild dementia, and moderate dementia) 
and education levels.
Furthermore, MAKS seems to be suitable for all ADL 
ability levels that were included in the study. Individuals with 
different ADL abilities improved on different criteria—those 
with better ADL abilities had a better chance of improving 
on the cognition criterion (MMSE), and those with lower 
ADL abilities had a better chance of improving on the ADL 
criterion (ETAM) itself. Hence, low ADL abilities do not 
imply that change is no longer possible, but improvement may 
happen.
For response on the BPSD criterion, the BPSD score at 
baseline is important. When defined by the BPSD criterion, 
responders had a mean NPI-Q score slightly above the mean 
of the whole IG sample, whereas non-responders’ mean NPI-Q 
score was almost one point below. There might be a minimum 
number of BPSD symptoms that render improvement visible 
on statistical tests (ceiling effect).
However, using these variables to make predictions 
is limited. The baseline variables that differed between 
responders and non-responders (the ETAM scores for 
cognition and ADL; the NPI-Q score for BPSD) displayed a 
TABLE 4 | Comparison of responders and non-responders in the IG for the response criteria “cognition,” “ADL,” and “BPSD.”
p for group differences between responders and 
non-responders
Cognition 
(MMSE)
ADL (ETAM) BPSD (NPI-Q)
PWD variables at baseline Age (in years) 0.882a 0.409a 0.586a
Sex (female)  >0.999b  >0.999b 0.541b
Education (years of school 
attendance)
 <8 years
8–9 years
9–10 years
12–13 years
University
0.280b 0.359b 0.872b
Dementia symptoms Cognition (MMSE) 0.190a 0.864a 0.427a
ADL (ETAM) 0.004a  <0.001a 0.353a
BPSD (NPI-Q) 0.636a 0.087a 0.005a
Medical variables Charlson Comorbidity Index 0.371a 0.836a 0.641a
Anti-dementia drugs1 (yes) 0.761b 0.757b 0.517b
Care level 0.639a 0.270a 0.845a
Depression (NPI-Q) 0.949a 0.551a 0.675a
CNS depressant score 0.342a 0.202a 0.696a
Orthopedic diseases 0.539b  >0.999b 0.508b
Neurological diseases 0.734b 0.608b  >0.999b
Caregiver variables at baseline Age (in years) 0.523a 0.457a 0.233a
Sex (female) 0.637b 0.263b 0.737b
Education (years of school 
attendance)
 <8 years
8–9 years
9–10 years
12–13 years
University
0.021b 0.719b 0.905b
Burden (BSFC-s) 0.205a 0.635a 0.085a
Benefits (BIZA-D) 0.767a 0.845a 0.209a
Degree of kinship to the PWD 0.931b 0.871b 0.380b
Living in the same house with the PWD 0.962b 0.190b 0.308b
aMann-Whitney U-test; bChi², Fisher’s exact test; 1CEIs or memantine. 
ADL, Activities of daily living; BIZA-D, The Berlin inventory of caregivers’ burden with dementia patients (Berliner Inventar zur Angehörigenbelastung – Demenz); BSFC-s, Burden 
Scale for Family Caregivers – short version, CNS, central vervous system; ETAM, Erlangen test of activities of daily living in persons with mild dementia or mild cognitive impairment; 
MMSE, Mini-mental state examination; NPI-Q, Neuropsychiatric inventory questionnaire.
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tendency but are not suitable for making valid predictions 
because only less than 70% of the responders could be 
classified correctly with each of them.
In most of the responder analyses using CEIs, no significant 
predictors of response (38) were found. If predictors were found in 
CEI studies, they were medical factors such as concomitant diseases 
(5, 19). We did not find that concomitant diseases were associated 
with response on any criterion, not when measured with the 
Charlson Comorbidity Index or as particular comorbidities such 
as orthopedic or neurological diseases. All variables associated 
with response were instead related to dementia symptoms (ADL 
and BPSD). Because CEI studies usually focus only on the PWD, 
we also involved the informal caregiver variables in our study as 
additional potential predictors. However, we also did not find that 
any of them were predictive of response.
Factors Regarding the Environment of 
the PWD
Of the factors pertaining to the environment of the PWD (e.g., 
living alone or living with the caregiving relative, burden, 
age, sex, or education of the caregiver), only caregivers` 
education significantly influenced PWDs` response to the 
multicomponent non-pharmacological MAKS intervention. 
The caregivers` education level might be a proxy for a 
stimulating environment beside day care for the PWD. 
Caregivers with high education might foster cognitive 
stimulation in their relatives` everyday life more strongly than 
caregivers with lower education. This might cause a ceiling 
effect. In general, it is important for individuals with dementia 
to be provided with a stimulating environment because they 
often no longer have the abilities or opportunities to actively 
seek such stimulation on their own.
Strengths and Limitations
Our study has several strengths. First, this is the first responder 
analysis for a non-pharmacological treatment in cognitively 
impaired persons. Second, we investigated patient-reported 
outcomes and personally relevant constructs, and cognition and 
ADL abilities were assessed via performance tests. Third, the 
sample size was sufficiently high with n = 362 individuals with 
cognitive impairment in day-care settings.
In health-services research, there is general agreement that 
response criteria with respect to the success of a therapeutic 
approach should not be based solely on expert ratings or 
characteristic parameters but should include patient-reported 
outcomes (“PROs”) (39). Researchers have suggested (40) that 
there is a need for research concerning the definition of patient-
relevant endpoints that reflect the patient’s perspective on 
satisfaction with the care or treatment received (41). Research 
on PROs usually focuses on patients with physical impairments 
who are cognitively unaffected (42). However, for people with 
cognitive impairments, a reliable and valid self-rating is severely 
limited. Therefore, performance tests (e.g., in our study, the 
MMSE [cognition] and the ETAM [ADL]) have to be preferred.
On the other hand, our study has some limitations. First, the 
data referred only to the day-care setting, and thus, we do not 
know if the findings can be generalized to nursing home patients 
or individuals with dementia living in the community without 
formal support measures. Second, the MMSE is easy to administer 
and is often used in clinical studies, but it has a limited sensitivity 
to change. It would therefore be desirable to replicate our results 
using a more sensitive performance test for cognition. Third, there 
might be predictors or moderators of response that we could 
not find because we did not collect them (e.g., social network 
strength, neurophysiological markers, or Big Five personality 
factors). Fourth, it has to be noted, that 36.5% of the participants 
in our study did not have an “official” dementia diagnosis from a 
physician (but were classified by MMSE and MoCA). This might 
be due to recruitment of study participants in “normal” day-care 
settings (where a dementia diagnosis is not necessary and might 
sometimes not be transferred from the patient charts to the day-
care patient charts) and not in specialized memory clinics or 
memory consultation centers. Furthermore, there are no incentives 
for physicians to diagnose dementia and no obligatory nationwide 
epidemiological registries to record these data in Germany.
CONCLUSION
The response rates from MAKS therapy were the same in size or 
higher than those reported for anti-dementia drugs. There were 
only a few differences between responders and non-responders 
on the response criteria cognition, activities of daily living, and 
behavioral and psychological symptoms of dementia. Furthermore, 
these differences were of limited value for prediction because the 
rate of correct classifications was low. Responses to these non-
pharmacological interventions did not seem to be predictable. 
Thus, MAKS therapy seemed to be suitable to the same degree 
for all participants included in this study—individuals with mild 
cognitive impairment, mild dementia, or moderate dementia. No 
special selection criteria are needed for the application of MAKS 
therapy in day-care facilities.
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